Skip to main content
Conference Coverage

Award-Winning CPC 2026 Research Examines Perioperative Treatment Costs in Muscle-Invasive Bladder Cancer

Edited by 

Key Takeaways: 

  • An economic analysis presented at Clinical Pathways Congress (CPC) 2026 estimated that perioperative durvalumab plus gemcitabine and cisplatin was associated with 31.1% lower total costs over 2 years compared with enfortumab vedotin plus pembrolizumab in patients with cisplatin-eligible muscle-invasive bladder cancer.
  • Estimated 2-year costs were $339 366 per patient for durvalumab plus chemotherapy and $492 707 for enfortumab vedotin plus pembrolizumab, with drug acquisition accounting for most of the difference.
  • The analysis also found lower estimated costs per event-free patient and per surviving patient with durvalumab plus chemotherapy, although the unadjusted cross-trial comparison does not establish comparative clinical efficacy or cost-effectiveness.

An economic analysis of 2 perioperative treatment regimens for cisplatin-eligible muscle-invasive bladder cancer (MIBC) identified substantial differences in estimated treatment costs, highlighting the growing importance of economic evidence in oncology clinical pathway development.

At CPC 2026, Simran Shokar, MPH, of AstraZeneca, presented the research, Cost and Cost per Patient Achieving Key Clinical Outcomes with Perioperative Durvalumab Plus Chemotherapy Versus Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Eligible Muscle-Invasive Bladder Cancer, which received the 2026 Journal of Clinical Pathways Innovative Abstract Award.

The study evaluated the total cost of care and cost per clinical outcome associated with the 2 treatment strategies over a 2-year period from a US all-payer perspective.

Evolving Treatment Options Introduce New Pathway Considerations

MIBC accounts for approximately 20% to 25% of bladder cancers and is associated with substantial risks of recurrence, progression, and mortality. The estimated 5-year overall survival probability ranges from 40% to 70%.

The financial burden is also considerable, with mean annual all-cause costs exceeding $130 000 per patient among individuals undergoing surgery.

Historically, perioperative treatment for cisplatin-eligible MIBC involved cisplatin-based chemotherapy followed by radical cystectomy.

However, the introduction of immunotherapy-based regimens has expanded treatment options.

The NIAGARA regimen consists of neoadjuvant durvalumab plus gemcitabine and cisplatin followed by surgery and adjuvant durvalumab.

The KEYNOTE-B15/EV-304 regimen combines enfortumab vedotin and pembrolizumab before and after surgery.

Shokar emphasized that clinical pathway decisions must balance clinical appropriateness, efficacy, safety, patient preferences, treatment delivery, and financial impact.

The economic analysis was designed to provide additional information about the financial implications of these treatment approaches.

Economic Model Evaluates 2-Year Treatment Costs

Researchers developed a decision tree model incorporating clinical outcomes from the NIAGARA and KEYNOTE-B15/EV-304 trials.

The model evaluated 3 health states: event-free, postevent, and death. Event-free survival and overall survival data from each trial were used to estimate monthly outcomes and associated costs over 24 months.

Costs included treatment acquisition and administration, surgery and readmissions, adverse event management, disease management, and patient travel.

Drug acquisition costs were estimated using wholesale acquisition costs, while treatment exposure reflected the mean number of cycles administered in each trial.

The analysis incorporated a weighted blend of commercial insurance, Medicare, and Medicaid, with all costs expressed in 2026 US dollars.

Importantly, the researchers did not conduct a formal indirect treatment comparison or network meta-analysis. Instead, each regimen was evaluated using outcomes from its respective clinical trial.

Durvalumab-Based Regimen Associated With Lower Estimated Costs

The model estimated total 2-year costs of $339 366 per patient for durvalumab plus gemcitabine and cisplatin compared with $492 707 for enfortumab vedotin plus pembrolizumab.

This represented a difference of $153 341 per patient, or 31.1% lower total costs with the durvalumab-based regimen.

Drug acquisition was the primary contributor to the difference.

Estimated acquisition costs were $147 470 for durvalumab plus chemotherapy compared with $313 428 for enfortumab vedotin plus pembrolizumab, representing a difference of $165 958.

However, disease management costs were higher with durvalumab plus chemotherapy, at $140 174 compared with $126 668 for enfortumab vedotin plus pembrolizumab, partially offsetting the drug acquisition savings.

Other cost categories, including surgery, administration, adverse event management, and patient travel, were generally similar between regimens.

The findings demonstrate how differences in treatment acquisition costs can substantially influence the overall economic burden of perioperative oncology care.

Cost per Clinical Outcome Provides Additional Context

Researchers also evaluated costs relative to the proportion of patients achieving key clinical outcomes at 2 years.

The reported 24-month event-free survival probabilities were 67.8% for durvalumab plus chemotherapy in NIAGARA and 79.4% for enfortumab vedotin plus pembrolizumab in KEYNOTE-B15/EV-304.

Corresponding overall survival probabilities were 82.2% and 86.9%, respectively.

Using these trial-specific outcomes, the estimated cost per event-free patient was $500 540 with durvalumab plus chemotherapy compared with $620 538 with enfortumab vedotin plus pembrolizumab, a difference of $119 998.

The estimated cost per surviving patient was $412 854 and $566 982, respectively, representing a difference of $154 128.

Although the durvalumab-based regimen demonstrated lower estimated costs per clinical outcome, these calculations were based on unadjusted results from separate clinical trials.

The researchers cautioned that differences in patient populations, study designs, and treatment exposure prevent these findings from establishing comparative efficacy or cost-effectiveness.

Implications for Oncology Clinical Pathways

The findings provide economic context for pathway committees evaluating perioperative treatment options for cisplatin-eligible MIBC.

As treatment options expand, understanding the costs associated with drug acquisition, administration, adverse event management, and downstream care may help stakeholders evaluate the financial implications of different treatment strategies.

However, the researchers acknowledged several limitations, including differences in baseline patient characteristics between NIAGARA and KEYNOTE-B15/EV-304 and the absence of statistical adjustment for cross-trial differences.

Additionally, the model used wholesale acquisition costs rather than payer-specific net prices, meaning actual expenditures may vary depending on negotiated discounts and rebates.

Future research could incorporate adjusted indirect treatment comparisons, longer-term outcomes, and payer-specific pricing to strengthen the economic evidence available for clinical pathway development.

Conclusion

The CPC 2026 award-winning analysis estimated that perioperative durvalumab plus gemcitabine and cisplatin was associated with lower 2-year total costs and lower costs per event-free or surviving patient compared with enfortumab vedotin plus pembrolizumab.

The findings highlight the importance of integrating economic evidence into oncology clinical pathway discussions while recognizing that treatment selection must also account for clinical efficacy, safety, patient characteristics, and preferences.

Reference 

Wang S, Shafrin J, Marin M, et al. Cost and cost per patient achieving key clinical outcomes with perioperative durvalumab plus chemotherapy versus enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer. Abstract presented at: Clinical Pathways Congress; November 10-11, 2026; Boston, MA.